Stock HWEL HEALTHWELL ACQUISITION CORP. I
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Healthwell Acquisition Corp. I

Equities

HWEL

US42227R1095

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Healthwell Acquisition Corp. I(NasdaqCM:HWEL) dropped from NASDAQ Composite Index
CI
HEALTHWELL ACQUISITION CORP. I ANNOUNCES CANCELLATION OF SPECIAL STOCKHOLDER MEETING AND ITS INTENTION TO LIQUIDATE
AQ
Healthwell Acquisition Plans to Liquidate
MT
Healthwell Acquisition Corp. I Announces Cancellation of Special Stockholder Meeting and its Intention to Liquidate
BU
Starton Therapeutics Announces Termination of Business Combination Agreement with Healthwell Acquisition Corp. I
AQ
Healthwell Acquisition Corp. I Announces Termination of Business Combination with Starton Therapeutics, Inc.
BU
Starton Therapeutics, Inc. cancelled the acquisition of Healthwell Acquisition Corp. I from a group of shareholders in a reverse merger transaction.
CI
Healthwell Acquisition Corp. I Announces Postponement of the Special Meeting of Stockholders to Approve the Proposed Business Combination with Starton Therapeutics, Inc. and Related Transactions
BU
Healthwell Acquisition Corp. I Announces New Meeting Date for the Special Meeting of Stockholders to Approve Proposed Business Combination With Starton Therapeutics, Inc. and Related Transactions
BU
Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma
BU
Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma
BU
Top Premarket Gainers
MT
Healthwell Acquisition Corp. I Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma
BU
Healthwell Acquisition I : Shareholder Director Nominations - Form 8-K
PU
HEALTHWELL ACQUISITION CORP. I : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma
BU
Starton Therapeutics, Inc. and Healthwell Acquisition Corp. I to Present at the Jefferies Healthcare Conference
BU
Healthwell Acquisition Corp. I Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
HEALTHWELL ACQUISITION CORP. I : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HWEL Stock
  4. News Healthwell Acquisition Corp. I